Advertisement

Document › Details
Ablynx N.V.. (1/5/17). "Press Release: Ablynx to Present at the 35th J.P. Morgan Healthcare Conference". Ghent.
![]() |
Region | San Francisco, CA |
Country | United States (USA) | |
![]() |
Organisation | Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX) |
Group | Sanofi (Group) [since May 2011] | |
Organisation 2 | J.P. Morgan Securities plc | |
Group | JPMorgan Chase (Group) | |
![]() |
Product | J.P. Morgan 35th Annual Healthcare Conference 2017 San Francisco |
Product 2 | Nanobodies® (Ablynx) | |
![]() |
Index term | Ablynx–JPMorgan Chase: investor conference, 201701 supply service Ablynx presents at JP Morgan Healthcare Conference 2017 |
![]() |
Person | Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry) |
Person 2 | Vermeersch, Marieke (Galapagos 202112– Head of Corp Communcations before Hyloris + AgroSavfe + Ablynx + Degroof) | |
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday 11 January 2017 at 4:30 p.m. Pacific Standard Time (1.30 a.m. on Thursday 12 January, Central European Time).
The presentation will be given by Dr Edwin Moses, CEO of Ablynx, and a breakout session will follow immediately.
The presentation will be webcast live and can be accessed on the day via this link. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast. A replay of the webcast will be available on the Company’s website, under the news & events section, for 90 days following the presentation.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact:
Ablynx
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Marieke Vermeersch
Director IR & Corporate Communications
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
@AblynxABLX
Ablynx media/analyst relations:
FTI Consulting
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: ablynx@fticonsulting.com
Disclaimer
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Record changed: 2023-06-05 |
Advertisement

More documents for Sanofi (Group) [since May 2011]
- [1] Sanofi S.A.. (3/13/23). "Press Release: Sanofi to Acquire Provention Bio, Adding to Portfolio TZIELD, the First Disease-modifying Treatment for the Delay of Stage 3 Type 1 Diabetes (T1D)". Paris & Red Bank, NJ....
- [2] Avilar Therapeutics, Inc.. (2/16/23). "Press Release: Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders". Waltham, MA....
- [3] Sanofi S.A.. (1/11/23). "Press Release: Sanofi Ventures Announces Multi-year Capital Commitment from Sanofi, Increasing Evergreen Fund to $750M". Paris....
- [4] CureVac N.V.. (1/10/23). "Press Release: CureVac Appoints Alexander Zehnder as CEO from April 1, 2023". Mainz & London....
- [5] Insilico Medicine. (11/8/22). "Press Release: Insilico Medicine Signs Strategic Research Collaboration with Sanofi Worth up to $1.2 Billion". New York, NY....
- [6] Matchpoint Therapeutics, Inc.. (10/14/22). "Press Release: Matchpoint Therapeutics Launches with $100 Million to Deliver on the Promise of Precision Covalent Medicines for Immune Diseases". Cambridge, MA....
- [7] Owkin. (10/4/22). "Press Release: Owkin Appoints Sanofi’s Global Head of Partnering Alban de La Sablière as Chief Business Officer"....
- [8] Sanofi S.A.. (8/4/22). "Press Release: Sanofi and Innovent Biologics Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China". Paris....
- [9] BeiGene, Ltd.. (7/13/22). "Press Release: BeiGene Appoints Chan Lee as General Counsel". Cambridge, MA, Basel & Beijing....
- [10] Glycomine, Inc.. (7/11/22). "Press Release: Glycomine Appoints Steven Axon as CEO and Adds Two New Board Directors". San Carlos, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top